Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer.
Adult
Aged
Antibodies, Immobilized
/ chemistry
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Epithelial Cell Adhesion Molecule
/ immunology
ErbB Receptors
/ genetics
Extracellular Vesicles
/ metabolism
Female
Gene Rearrangement
Humans
Lung Neoplasms
/ genetics
Male
Middle Aged
Nanowires
/ chemistry
Polymerase Chain Reaction
Polymorphism, Single Nucleotide
Protein-Tyrosine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
RNA, Messenger
/ metabolism
Silicon
/ chemistry
EGFR T790M mutation
ROS1 rearrangements
extracellular vesicles
microfluidics
nanosubstrates
non-small cell lung cancer
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
17 Apr 2019
17 Apr 2019
Historique:
pubmed:
21
3
2019
medline:
14
8
2019
entrez:
21
3
2019
Statut:
ppublish
Résumé
Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.
Identifiants
pubmed: 30892008
doi: 10.1021/acsami.9b01406
pmc: PMC6545291
mid: NIHMS1028110
doi:
Substances chimiques
Antibodies, Immobilized
0
Biomarkers, Tumor
0
Epithelial Cell Adhesion Molecule
0
Proto-Oncogene Proteins
0
RNA, Messenger
0
ErbB Receptors
EC 2.7.10.1
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Silicon
Z4152N8IUI
Types de publication
Journal Article
Langues
eng
Pagination
13973-13983Subventions
Organisme : NCI NIH HHS
ID : R21 CA216807
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218356
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA235340
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001882
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA198900
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA253651
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA246304
Pays : United States
Références
J Immunol Methods. 2002 Dec 15;270(2):211-26
pubmed: 12379326
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Nat Commun. 2011 Feb 01;2:180
pubmed: 21285958
Angew Chem Int Ed Engl. 2011 Mar 21;50(13):3084-8
pubmed: 21374764
Methods. 2012 Feb;56(2):293-304
pubmed: 22285593
Anal Biochem. 2012 Sep 1;428(1):44-53
pubmed: 22691960
BMC Cancer. 2012 Sep 24;12:421
pubmed: 22998595
Lab Chip. 2012 Dec 21;12(24):5202-10
pubmed: 23111789
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
J Neurooncol. 2013 May;113(1):1-11
pubmed: 23456661
Lab Chip. 2013 Aug 7;13(15):2879-82
pubmed: 23743667
Methods. 2013 Dec 1;64(2):144-52
pubmed: 23816790
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Front Genet. 2013 Jul 30;4:142
pubmed: 23908664
Proteomics. 2013 Nov;13(22):3354-64
pubmed: 24115447
Clin Biochem. 2014 Jan;47(1-2):135-8
pubmed: 24183884
Lab Chip. 2014 Jan 7;14(1):89-98
pubmed: 24220648
Lab Chip. 2014 Jun 7;14(11):1891-900
pubmed: 24722878
Clin Ther. 2014 Jun 1;36(6):830-46
pubmed: 24952934
Clin Biochem. 2014 Sep;47(13-14):1286-92
pubmed: 24956264
Acc Chem Res. 2014 Oct 21;47(10):2941-50
pubmed: 25111636
J Chromatogr A. 2014 Dec 5;1371:125-35
pubmed: 25458527
BMC Cancer. 2014 Dec 16;14:962
pubmed: 25510783
Trends Cell Biol. 2015 Jun;25(6):364-72
pubmed: 25683921
Transl Lung Cancer Res. 2015 Apr;4(2):156-64
pubmed: 25870798
Cancers (Basel). 2015 May 26;7(2):930-49
pubmed: 26018876
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Lab Chip. 2016 Feb 7;16(3):489-96
pubmed: 26645590
J Hematol Oncol. 2016 Apr 12;9:34
pubmed: 27071706
Theranostics. 2016 Jun 15;6(9):1425-39
pubmed: 27375790
Nat Nanotechnol. 2016 Nov;11(11):936-940
pubmed: 27479757
Biotechnol J. 2017 Apr;12(4):
pubmed: 28166394
Methods Mol Biol. 2017;1660:33-41
pubmed: 28828646
Sci Rep. 2017 Sep 14;7(1):11561
pubmed: 28912498
Clin Cancer Res. 2018 Jan 1;24(1):181-188
pubmed: 29051321
Mol Aspects Med. 2018 Apr;60:27-37
pubmed: 29155161
Cancers (Basel). 2017 Nov 30;9(12):null
pubmed: 29189709
Adv Drug Deliv Rev. 2018 Feb 1;125:36-47
pubmed: 29247765
Nat Commun. 2018 Jan 12;9(1):175
pubmed: 29330365
Clin Cancer Res. 2018 Jun 15;24(12):2944-2950
pubmed: 29535126
Adv Drug Deliv Rev. 2018 Feb 1;125:78-93
pubmed: 29551650
N Engl J Med. 2018 Sep 06;379(10):958-966
pubmed: 30184457